Clinical studies confirmed that anti-TNF-α treatment by infliximab increased muscle mass in patients with Crohn's disease (26), while patients with RA gained appendicular lean mass after tocilizumab treatment by inhibiting IL-6 (27). Here, TNF is linked to Crohn disease.